HIMS
Price
$49.77
Change
-$9.38 (-15.86%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
13.37B
17 days until earnings call
HROW
Price
$40.03
Change
+$2.11 (+5.56%)
Updated
Oct 17, 04:59 PM (EDT)
Capitalization
1.4B
31 days until earnings call
Interact to see
Advertisement

HIMS vs HROW

Header iconHIMS vs HROW Comparison
Open Charts HIMS vs HROWBanner chart's image
Hims & Hers Health
Price$49.77
Change-$9.38 (-15.86%)
Volume$537.78K
Capitalization13.37B
Harrow
Price$40.03
Change+$2.11 (+5.56%)
Volume$9.76K
Capitalization1.4B
HIMS vs HROW Comparison Chart in %
View a ticker or compare two or three
VS
HIMS vs. HROW commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HIMS is a Hold and HROW is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (HIMS: $59.15 vs. HROW: $37.92)
Brand notoriety: HIMS and HROW are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: HIMS: 139% vs. HROW: 79%
Market capitalization -- HIMS: $11.25B vs. HROW: $1.48B
HIMS [@Pharmaceuticals: Generic] is valued at $11.25B. HROW’s [@Pharmaceuticals: Generic] market capitalization is $1.48B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.85B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.95B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HIMS’s FA Score shows that 0 FA rating(s) are green whileHROW’s FA Score has 1 green FA rating(s).

  • HIMS’s FA Score: 0 green, 5 red.
  • HROW’s FA Score: 1 green, 4 red.
According to our system of comparison, HROW is a better buy in the long-term than HIMS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HIMS’s TA Score shows that 7 TA indicator(s) are bullish while HROW’s TA Score has 5 bullish TA indicator(s).

  • HIMS’s TA Score: 7 bullish, 2 bearish.
  • HROW’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, HIMS is a better buy in the short-term than HROW.

Price Growth

HIMS (@Pharmaceuticals: Generic) experienced а +1.55% price change this week, while HROW (@Pharmaceuticals: Generic) price change was -6.53% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.01%. For the same industry, the average monthly price growth was +4.92%, and the average quarterly price growth was +52.54%.

Reported Earning Dates

HIMS is expected to report earnings on Nov 03, 2025.

HROW is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.01% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HIMS($13.4B) has a higher market cap than HROW($1.4B). HIMS YTD gains are higher at: 144.624 vs. HROW (13.025). HIMS has higher annual earnings (EBITDA): 155M vs. HROW (32.1M). HIMS has more cash in the bank: 1.15B vs. HROW (53M). HROW has less debt than HIMS: HROW (231M) vs HIMS (1.04B). HIMS has higher revenues than HROW: HIMS (2.01B) vs HROW (228M).
HIMSHROWHIMS / HROW
Capitalization13.4B1.4B955%
EBITDA155M32.1M483%
Gain YTD144.62413.0251,110%
P/E Ratio74.87N/A-
Revenue2.01B228M883%
Total Cash1.15B53M2,160%
Total Debt1.04B231M452%
FUNDAMENTALS RATINGS
HIMS vs HROW: Fundamental Ratings
HIMS
HROW
OUTLOOK RATING
1..100
1772
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
4147
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9091
P/E GROWTH RATING
1..100
999
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HROW's Valuation (82) in the Pharmaceuticals Other industry is in the same range as HIMS (92) in the null industry. This means that HROW’s stock grew similarly to HIMS’s over the last 12 months.

HIMS's Profit vs Risk Rating (41) in the null industry is in the same range as HROW (47) in the Pharmaceuticals Other industry. This means that HIMS’s stock grew similarly to HROW’s over the last 12 months.

HIMS's SMR Rating (100) in the null industry is in the same range as HROW (100) in the Pharmaceuticals Other industry. This means that HIMS’s stock grew similarly to HROW’s over the last 12 months.

HIMS's Price Growth Rating (90) in the null industry is in the same range as HROW (91) in the Pharmaceuticals Other industry. This means that HIMS’s stock grew similarly to HROW’s over the last 12 months.

HROW's P/E Growth Rating (9) in the Pharmaceuticals Other industry is significantly better than the same rating for HIMS (99) in the null industry. This means that HROW’s stock grew significantly faster than HIMS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HIMSHROW
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
87%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 17 days ago
80%
Bearish Trend 10 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
HIMS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CRLVX11.420.01
+0.09%
Catholic Rspnsbl Invstmnts Intl Eq Inv
FEQIX83.59N/A
N/A
Fidelity Equity-Income
MUHLX74.21-0.12
-0.16%
Muhlenkamp
SFMIX43.43-0.32
-0.73%
American Beacon Stephens Mid-Cap Gr R5
WESWX11.36-0.12
-1.05%
TETON Westwood Equity AAA

HIMS and

Correlation & Price change

A.I.dvisor tells us that HIMS and COTY have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HIMS and COTY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HIMS
1D Price
Change %
HIMS100%
-5.75%
COTY - HIMS
31%
Poorly correlated
-2.12%
EWCZ - HIMS
30%
Poorly correlated
-0.29%
HROW - HIMS
29%
Poorly correlated
-3.85%
ALKS - HIMS
27%
Poorly correlated
-4.44%
ETON - HIMS
25%
Poorly correlated
-4.23%
More

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with OGI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then OGI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
-3.85%
OGI - HROW
34%
Loosely correlated
-3.57%
AMRX - HROW
32%
Poorly correlated
+0.92%
TKNO - HROW
32%
Poorly correlated
-2.41%
ELAN - HROW
30%
Poorly correlated
+0.05%
AMPH - HROW
29%
Poorly correlated
+0.35%
More